BR112018008081A2 - métodos para a cultura de células e kits e aparelho para os mesmos - Google Patents
métodos para a cultura de células e kits e aparelho para os mesmosInfo
- Publication number
- BR112018008081A2 BR112018008081A2 BR112018008081A BR112018008081A BR112018008081A2 BR 112018008081 A2 BR112018008081 A2 BR 112018008081A2 BR 112018008081 A BR112018008081 A BR 112018008081A BR 112018008081 A BR112018008081 A BR 112018008081A BR 112018008081 A2 BR112018008081 A2 BR 112018008081A2
- Authority
- BR
- Brazil
- Prior art keywords
- agents
- methods
- proliferation
- expansion
- stimulation
- Prior art date
Links
- 238000004113 cell culture Methods 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 abstract 7
- 210000004027 cell Anatomy 0.000 abstract 5
- 239000003153 chemical reaction reagent Substances 0.000 abstract 5
- 238000000034 method Methods 0.000 abstract 3
- 230000035755 proliferation Effects 0.000 abstract 3
- 230000004936 stimulating effect Effects 0.000 abstract 3
- 230000000638 stimulation Effects 0.000 abstract 3
- 230000004913 activation Effects 0.000 abstract 2
- 230000004940 costimulation Effects 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 230000004083 survival effect Effects 0.000 abstract 2
- 238000011534 incubation Methods 0.000 abstract 1
- 210000004698 lymphocyte Anatomy 0.000 abstract 1
- 230000001151 other effect Effects 0.000 abstract 1
- 230000002688 persistence Effects 0.000 abstract 1
- 239000000376 reactant Substances 0.000 abstract 1
- 230000002441 reversible effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0635—B lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/21—Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/52—CD40, CD40-ligand (CD154)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2523/00—Culture process characterised by temperature
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/20—Small organic molecules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
fornecidos aqui são os métodos que relatam, em alguns aspectos, à incubação ou cultura, tal como para induzir a estimulação da expansão (proliferação), ativação, coestimulação e / ou sobrevivência, de uma composição de células, tal como uma população de linfócitos. em alguns aspectos, fornecidos são métodos e reagentes para a estimulação, por exemplo, de expansão (proliferação), sobrevivência ou persistência, ativação, coestimulação, ou outro efeito, de populações de célula que envolvem a ligação de agentes a uma molécula sobre a superfície das células, desse modo fornecendo um ou mais sinais às células. em alguns casos, os reagentes são reagentes contendo uma pluralidade de sítios de ligação para agentes, tais como reagentes de multimerização, e desse modo a um ou mais agentes são multimerizados ligando-se reversivelmente ao reagente, por exemplo, desse modo criando um reagente estimulatório (agente multimerizado), tendo agentes estimulatórios neste. em alguns aspectos, o agente multimerizado pode fornecer para expansão ou proliferação ou outra estimulação de uma população de células, e em seguida tais agentes estimulatórios podem ser removidos por ruptura da ligação reversível. da mesma forma fornecidos são as composições, aparelhos e métodos de uso dos mesmos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562245261P | 2015-10-22 | 2015-10-22 | |
US201562245252P | 2015-10-22 | 2015-10-22 | |
PCT/IB2016/001618 WO2017068421A1 (en) | 2015-10-22 | 2016-10-20 | Methods for culturing cells and kits and apparatus for same |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112018008081A2 true BR112018008081A2 (pt) | 2018-11-13 |
Family
ID=57394616
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018008081A BR112018008081A2 (pt) | 2015-10-22 | 2016-10-20 | métodos para a cultura de células e kits e aparelho para os mesmos |
Country Status (17)
Country | Link |
---|---|
US (2) | US11466253B2 (pt) |
EP (1) | EP3365434A1 (pt) |
JP (3) | JP6895959B2 (pt) |
KR (1) | KR20180100110A (pt) |
CN (2) | CN117106716A (pt) |
AU (1) | AU2016341529B2 (pt) |
BR (1) | BR112018008081A2 (pt) |
CA (1) | CA3002745A1 (pt) |
HK (1) | HK1258931A1 (pt) |
IL (2) | IL307934A (pt) |
MA (1) | MA45488A (pt) |
MX (3) | MX2018004874A (pt) |
NZ (1) | NZ741878A (pt) |
PH (1) | PH12018500860A1 (pt) |
RU (1) | RU2761557C2 (pt) |
SG (1) | SG11201803330WA (pt) |
WO (1) | WO2017068421A1 (pt) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005047482A2 (en) | 2003-11-12 | 2005-05-26 | Xiao Xu | Real time electronic cell sensing systems and applications for cell-based assays |
US8263375B2 (en) | 2002-12-20 | 2012-09-11 | Acea Biosciences | Dynamic monitoring of activation of G-protein coupled receptor (GPCR) and receptor tyrosine kinase (RTK) in living cells using real-time microelectronic cell sensing technology |
US10539523B2 (en) | 2002-12-20 | 2020-01-21 | Acea Biosciences, Inc. | System and method for monitoring cardiomyocyte beating, viability, morphology, and electrophysiological properties |
US10551371B2 (en) | 2003-11-10 | 2020-02-04 | Acea Biosciences, Inc. | System and method for monitoring cardiomyocyte beating, viability and morphology and for screening for pharmacological agents which may induce cardiotoxicity or modulate cardiomyocyte function |
US10215748B2 (en) | 2002-12-20 | 2019-02-26 | Acea Biosciences, Inc. | Using impedance-based cell response profiling to identify putative inhibitors for oncogene addicted targets or pathways |
US11346797B2 (en) | 2002-12-20 | 2022-05-31 | Agilent Technologies, Inc. | System and method for monitoring cardiomyocyte beating, viability, morphology and electrophysiological properties |
EP2291645B1 (en) | 2008-05-05 | 2015-09-09 | Acea Biosciences, Inc. | Label-free monitoring of excitation-contraction coupling and excitable cells using impedance based systems with millisecond time resolution |
EP2817625A2 (en) | 2012-02-23 | 2014-12-31 | Stage Cell Therapeutics GmbH | Chromatographic isolation of cells and other complex biological materials |
MY184699A (en) | 2014-04-16 | 2021-04-18 | Juno Therapeutics Gmbh | Methods, kits and apparatus for expanding a population of cells |
JP7195141B2 (ja) | 2015-10-22 | 2022-12-23 | ジュノ セラピューティクス ゲーエムベーハー | 形質導入のための方法、キット、作用物質および装置 |
MA45489A (fr) | 2015-10-22 | 2018-08-29 | Juno Therapeutics Gmbh | Procédés de culture de cellules, kits et appareil associés |
US20190119636A1 (en) | 2017-10-23 | 2019-04-25 | Poseida Therapeutics, Inc. | Modified stem cell memory t cells, methods of making and methods of using same |
TWI788307B (zh) | 2016-10-31 | 2023-01-01 | 美商艾歐凡斯生物治療公司 | 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞 |
BR112019009925A2 (pt) | 2016-11-17 | 2019-10-08 | Iovance Biotherapeutics Inc | método para preparar linfócitos infiltrantes de tumor remanescente para terapia de células t adotivas, e, método de tratamento de um câncer . |
WO2018129336A1 (en) | 2017-01-06 | 2018-07-12 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof |
WO2018161063A1 (en) | 2017-03-03 | 2018-09-07 | Acea Biosciences, Inc. | METHODS AND SYSTEMS FOR FUNCTIONAL MATURATION OF iPSC AND ESC DERIVED CARDIOMYOCYTES |
CA3056630A1 (en) | 2017-03-15 | 2018-09-20 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
JOP20190224A1 (ar) | 2017-03-29 | 2019-09-26 | Iovance Biotherapeutics Inc | عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي |
US11254913B1 (en) | 2017-03-29 | 2022-02-22 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
NZ758485A (en) | 2017-04-27 | 2024-02-23 | Juno Therapeutics Gmbh | Oligomeric particle reagents and methods of use thereof |
CN111010866A (zh) | 2017-05-24 | 2020-04-14 | 潘迪恩治疗公司 | 靶向免疫耐受性 |
EP3630980B1 (en) * | 2017-06-01 | 2023-11-01 | Innovative Cellular Therapeutics Holdings, Ltd. | Chimeric antigen receptor cell preparation and uses thereof |
US11235004B2 (en) | 2017-06-30 | 2022-02-01 | Innovative Cellular Therapeutics Holdings, Ltd. | Lymphocyte cell lines and uses thereof |
EP3662281A4 (en) * | 2017-08-01 | 2021-04-21 | Agilent Technologies, Inc. | CELL SUBSTRATE IMPEDANCE MONITORING OF CANCER CELLS OF DIFFERENT LINE, ORIGIN OR STAGE |
JP7275104B2 (ja) | 2017-08-09 | 2023-05-17 | ジュノー セラピューティクス インコーポレイテッド | 遺伝子操作された細胞の組成物および関連組成物を産生するための方法 |
US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
AU2019284911A1 (en) | 2018-06-13 | 2020-12-17 | Novartis Ag | BCMA chimeric antigen receptors and uses thereof |
CN112585160A (zh) | 2018-08-06 | 2021-03-30 | 麦地金公司 | Il-2受体结合化合物 |
KR20210057730A (ko) * | 2018-08-09 | 2021-05-21 | 주노 쎄러퓨티크스 인코퍼레이티드 | 조작 세포 및 이의 조성물 생성 방법 |
WO2020047099A1 (en) * | 2018-08-28 | 2020-03-05 | Fred Hutchinson Cancer Research Center | Methods and compositions for adoptive t cell therapy incorporating induced notch signaling |
SG11202101825QA (en) * | 2018-08-31 | 2021-03-30 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
SG11202104355SA (en) * | 2018-10-31 | 2021-05-28 | Juno Therapeutics Gmbh | Methods for selection and stimulation of cells and apparatus for same |
WO2020097466A1 (en) | 2018-11-08 | 2020-05-14 | Neximmune, Inc. | T cell compositions with improved phenotypic properties |
CA3126066A1 (en) * | 2019-01-07 | 2020-07-16 | Children's National Medical Center | Ex vivo activated t-lymphocytic compositions and methods of using the same |
KR20200132147A (ko) * | 2019-05-15 | 2020-11-25 | 의료법인 성광의료재단 | 자연 살해 세포의 배양용 조성물 및 이를 이용한 방법 |
AU2020279240A1 (en) | 2019-05-20 | 2021-12-23 | Pandion Operations, Inc. | MAdCAM targeted immunotolerance |
AU2020377043A1 (en) | 2019-10-30 | 2022-06-02 | Juno Therapeutics Gmbh | Cell selection and/or stimulation devices and methods of use |
KR20220110207A (ko) | 2019-11-05 | 2022-08-05 | 메디카인 인코포레이티드 | IL-2RβγC 결합 화합물 |
KR102351020B1 (ko) * | 2019-11-20 | 2022-01-14 | 주식회사 지아이셀 | 자연살해세포 배양용 조성물 및 이를 이용한 자연살해세포 제조방법 |
CA3157613A1 (en) * | 2019-11-20 | 2021-05-27 | Gi Cell, Inc. | Medium composition for culturing t cells and method for culturing t cells using same |
CN114945382A (zh) | 2019-11-26 | 2022-08-26 | 诺华股份有限公司 | Cd19和cd22嵌合抗原受体及其用途 |
CA3161303A1 (en) * | 2019-11-27 | 2021-06-03 | Gi Innovation, Inc. | Pharmaceutical composition for treating cancer comprising fusion protein comprising il-2 protein and cd80 protein and immune checkpoint inhibitor |
CN115003818A (zh) * | 2020-01-22 | 2022-09-02 | 科济生物医药(上海)有限公司 | 病毒载体转导细胞的方法 |
US11746139B2 (en) | 2020-02-03 | 2023-09-05 | Medikine, Inc. | IL-7Rαγc binding compounds |
US11981715B2 (en) | 2020-02-21 | 2024-05-14 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a CD39 effector |
EP4240756A1 (en) | 2020-11-04 | 2023-09-13 | Juno Therapeutics, Inc. | Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods |
CN113125733A (zh) * | 2021-04-16 | 2021-07-16 | 浙江普罗亭健康科技有限公司 | 一种用于监测人体免疫状态的42抗体试剂盒及应用 |
CN113125718A (zh) * | 2021-04-16 | 2021-07-16 | 浙江普罗亭健康科技有限公司 | 一种用于监测人体免疫状态的45抗体试剂盒及应用 |
CN117916256A (zh) | 2021-05-06 | 2024-04-19 | 朱诺治疗学有限公司 | 用于刺激和转导t细胞的方法 |
WO2022254337A1 (en) | 2021-06-01 | 2022-12-08 | Novartis Ag | Cd19 and cd22 chimeric antigen receptors and uses thereof |
US11999771B2 (en) | 2022-04-07 | 2024-06-04 | Medikine, Inc. | IL-7Rαγc ligand immunoglobulin fusion proteins |
WO2023201369A1 (en) | 2022-04-15 | 2023-10-19 | Iovance Biotherapeutics, Inc. | Til expansion processes using specific cytokine combinations and/or akti treatment |
WO2023213969A1 (en) * | 2022-05-05 | 2023-11-09 | Juno Therapeutics Gmbh | Viral-binding protein and related reagents, articles, and methods of use |
WO2024124132A1 (en) | 2022-12-09 | 2024-06-13 | Juno Therapeutics, Inc. | Machine learning methods for predicting cell phenotype using holographic imaging |
Family Cites Families (162)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4361549A (en) | 1979-04-26 | 1982-11-30 | Ortho Pharmaceutical Corporation | Complement-fixing monoclonal antibody to human T cells, and methods of preparing same |
US4452773A (en) | 1982-04-05 | 1984-06-05 | Canadian Patents And Development Limited | Magnetic iron-dextran microspheres |
US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
JP2624470B2 (ja) | 1984-10-02 | 1997-06-25 | バイオジェン インコーポレイテッド | ストレプトアビジン様ポリペプチドの製造 |
US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
US4795698A (en) | 1985-10-04 | 1989-01-03 | Immunicon Corporation | Magnetic-polymer particles |
IN165717B (pt) | 1986-08-07 | 1989-12-23 | Battelle Memorial Institute | |
US4851341A (en) | 1986-12-19 | 1989-07-25 | Immunex Corporation | Immunoaffinity purification system |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
US6303121B1 (en) | 1992-07-30 | 2001-10-16 | Advanced Research And Technology | Method of using human receptor protein 4-1BB |
US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
ES2067018T3 (es) | 1988-12-28 | 1995-03-16 | Stefan Miltenyi | Procedimiento y materiales para la separacion en alto gradiente magnetico de materiales biologicos. |
US5200084A (en) | 1990-09-26 | 1993-04-06 | Immunicon Corporation | Apparatus and methods for magnetic separation |
AU650085B2 (en) | 1990-11-13 | 1994-06-09 | Immunex Corporation | Bifunctional selectable fusion genes |
DE4237113B4 (de) | 1992-11-03 | 2006-10-12 | "Iba Gmbh" | Peptide und deren Fusionsproteine, Expressionsvektor und Verfahren zur Herstellung eines Fusionsproteins |
WO1994028143A1 (en) | 1993-05-21 | 1994-12-08 | Targeted Genetics Corporation | Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene |
ES2240962T3 (es) | 1993-06-04 | 2005-10-16 | The United States Of America As Represented By The Secretary Of The Navy | Metodo para estimular selectivamente la proliferacion de celulas t. |
EP0638644A1 (en) | 1993-07-19 | 1995-02-15 | F. Hoffmann-La Roche Ag | Receptors of interleukin-12 and antibodies |
US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
AU5132096A (en) | 1995-01-30 | 1996-08-21 | Terrapin Technologies, Inc. | Glubodies - multiplicities of proteins capable of binding a variety of small molecules |
US5853721A (en) | 1995-01-31 | 1998-12-29 | Hoffmann-La Roche Inc. | Antibody to interleukin-12 receptor |
EP0815121A4 (en) | 1995-02-09 | 1999-09-01 | Univ Washington | MODIFIED AFFINITY STREPTAVIDINE |
US5795966A (en) | 1995-02-22 | 1998-08-18 | Immunex Corp | Antagonists of interleukin-15 |
CA2222035A1 (en) | 1995-04-11 | 1997-03-27 | Trustees Of Boston University | Streptavidin mutants |
DE19608753C1 (de) | 1996-03-06 | 1997-06-26 | Medigene Gmbh | Transduktionssystem und seine Verwendung |
WO1997034634A1 (en) | 1996-03-20 | 1997-09-25 | Sloan-Kettering Institute For Cancer Research | Single chain fv constructs of anti-ganglioside gd2 antibodies |
US6140064A (en) | 1996-09-10 | 2000-10-31 | Theodor-Kocher Institute | Method of detecting or identifying ligands, inhibitors or promoters of CXC chemokine receptor 3 |
DE19641876B4 (de) | 1996-10-10 | 2011-09-29 | Iba Gmbh | Streptavidinmuteine |
EP0977770A4 (en) | 1997-03-14 | 2000-04-05 | Univ Boston | DIFFERENTLY FLAVORED STREPTAVIDINE |
US5985658A (en) | 1997-11-14 | 1999-11-16 | Health Research Incorporated | Calmodulin-based cell separation technique |
US6153441A (en) | 1998-02-17 | 2000-11-28 | Smithkline Beecham Corporation | Methods of screening for agonists and antagonists for human CCR7 receptor and CKβ-9 ligand and interaction thereof |
US7198789B2 (en) | 1998-03-17 | 2007-04-03 | Genetics Institute, Llc | Methods and compositions for modulating interleukin-21 receptor activity |
DK1082141T3 (da) | 1998-05-23 | 2005-12-05 | Univ Leiden Medical Ct | CD40-bindende molekyler og CTL-peptider til behandling af tumorer |
EP1109921A4 (en) | 1998-09-04 | 2002-08-28 | Sloan Kettering Inst Cancer | FOR PROSTATE-SPECIFIC MEMBRANE-ANTI-SPECIFIC FUSION RECEPTORS AND THEIR USE |
WO2000023573A2 (en) | 1998-10-20 | 2000-04-27 | City Of Hope | Cd20-specific redirected t cells and their use in cellular immunotherapy of cd20+ malignancies |
KR20020013496A (ko) | 1999-02-04 | 2002-02-20 | 추후제출 | 조혈 간세포 및(또는) 전구세포의 유지 및 증대 방법 및장치 |
DE19932688B4 (de) | 1999-07-13 | 2009-10-08 | Scil Proteins Gmbh | Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen |
WO2001056603A1 (en) | 2000-02-01 | 2001-08-09 | Tanox, Inc. | Cd40-binding apc-activating molecules |
US20030235908A1 (en) * | 2000-02-24 | 2003-12-25 | Xcyte Therapies, Inc. | Activation and expansion of cells |
WO2001083755A2 (en) | 2000-04-28 | 2001-11-08 | La Jolla Institute For Allergy And Immunology | Human anti-cd40 antibodies and methods of making and using same |
US7063845B2 (en) | 2000-04-28 | 2006-06-20 | Gemini Science, Inc. | Human anti-CD40 antibodies |
EP1287357A2 (en) | 2000-06-02 | 2003-03-05 | Memorial Sloan-Kettering Cancer Center | Artificial antigen presenting cells and methods of use thereof |
MXPA03002278A (es) | 2000-09-14 | 2004-12-03 | Beth Israel Hospital | Modulacion de respuestas de la celula t mediadas por il-2 e il-15. |
CA2425862C (en) | 2000-11-07 | 2013-01-22 | City Of Hope | Cd19-specific redirected immune cells |
EP1227321A1 (en) * | 2000-12-28 | 2002-07-31 | Institut für Bioanalytik GmbH | Reversible MHC multimer staining for functional purification of antigen-specific T cells |
DE10113776B4 (de) | 2001-03-21 | 2012-08-09 | "Iba Gmbh" | Isoliertes streptavidinbindendes, kompetitiv eluierbares Peptid, dieses umfassendes Fusionspeptid, dafür codierende Nukleinsäure, Expressionsvektor, Verfahren zur Herstellung eines rekombinanten Fusionsproteins und Verfahren zum Nachweis und/oder zur Gewinnung des Fusionsproteins |
US7070995B2 (en) | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
CA2658221C (en) | 2001-04-27 | 2012-11-27 | Kyowa Hakko Kirin Co., Ltd. | Anti-cd40 monoclonal antibody |
US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
AU2002330053A1 (en) | 2001-09-20 | 2003-04-01 | Schering Corporation | Chemokines as adjuvants of immune response |
WO2003029462A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
JP2005536184A (ja) | 2002-03-01 | 2005-12-02 | エルドマン,ヴォルカー,エー. | ストレプトアビジン結合ペプチド |
US20030170238A1 (en) | 2002-03-07 | 2003-09-11 | Gruenberg Micheal L. | Re-activated T-cells for adoptive immunotherapy |
US7754155B2 (en) | 2002-03-15 | 2010-07-13 | Ross Amelia A | Devices and methods for isolating target cells |
WO2003090781A1 (en) | 2002-04-23 | 2003-11-06 | Meir Strahilevitz | Methods and devices for targeting a site in a mammal and for removing species from a mammal |
US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
WO2007001459A2 (en) | 2004-11-15 | 2007-01-04 | Washington University | Compositions and methods for modulating lymphocyte activity |
FR2841905B1 (fr) | 2002-07-05 | 2004-09-03 | Centre Nat Rech Scient | Fragments fab mutants de l'anticorps anti-cd4 chimere 13b8.2 et leurs applications |
CA2489410C (en) | 2002-07-17 | 2015-01-13 | Cytos Biotechnology Ag | Molecular antigen arrays |
EP1447093A1 (en) | 2003-02-14 | 2004-08-18 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Inhibition of the CD95 ligand/receptor system for the treatment of neurological disorders and injuries |
US20050129671A1 (en) | 2003-03-11 | 2005-06-16 | City Of Hope | Mammalian antigen-presenting T cells and bi-specific T cells |
KR20060015482A (ko) | 2003-03-21 | 2006-02-17 | 와이어쓰 | 인터루킨-21/인터루킨-21 수용체의 작용제를 이용한면역장애의 치료 |
JP2006524991A (ja) | 2003-05-08 | 2006-11-09 | エクサイト セラピーズ インコーポレーティッド | 抗原特異的t細胞の作製および単離の方法 |
US7943393B2 (en) | 2003-07-14 | 2011-05-17 | Phynexus, Inc. | Method and device for extracting an analyte |
JP4931597B2 (ja) | 2003-11-07 | 2012-05-16 | イミュネックス・コーポレーション | インターロイキン−4受容体を結合する抗体 |
JP2007512528A (ja) | 2003-11-20 | 2007-05-17 | バイオセンサー、アプリケーションズ、スエーデン、アクチボラグ | 所定の抗原混合物に特異的な少なくとも2種類の異なる抗体の混合物およびその混合物の使用 |
PT1711207E (pt) | 2003-12-10 | 2013-02-13 | Medarex Inc | Anticorpos alfa interferão e seus usos |
SE0400181D0 (sv) | 2004-01-29 | 2004-01-29 | Gyros Ab | Segmented porous and preloaded microscale devices |
EP1776583A4 (en) | 2004-02-26 | 2009-04-29 | Immunovative Therapies Ltd | PROCESSES FOR THE PREPARATION OF T CELLS FOR CELL THERAPY |
US7592431B2 (en) | 2004-02-26 | 2009-09-22 | Immunovative Therapies, Ltd. | Biodegradable T-cell Activation device |
EP1766400B1 (en) | 2004-06-03 | 2009-04-15 | Meso Scale Technologies, LLC | Methods for conducting whole blood assays |
AU2005258077C1 (en) | 2004-06-21 | 2012-10-25 | E. R. Squibb & Sons, L.L.C. | Interferon alpha receptor 1 antibodies and their uses |
CA2572334A1 (en) | 2004-07-01 | 2006-01-19 | New York University | Compositions and methods for modulation of ror.gamma.t |
EP1773394A2 (en) | 2004-08-05 | 2007-04-18 | Wyeth a Corporation of the State of Delaware | Antagonizing interleukin-21 receptor activity |
ATE536552T1 (de) | 2004-10-15 | 2011-12-15 | Danisco Us Inc | Kompetitven differential screening |
AU2004325035B2 (en) | 2004-11-12 | 2011-09-08 | Genentech, Inc. | Novel composition and methods for the treatment of immune related diseases |
WO2006058226A2 (en) | 2004-11-24 | 2006-06-01 | The Trustees Of Boston University | Modified dimeric streptavidins and uses thereof |
US20060252087A1 (en) | 2005-01-18 | 2006-11-09 | Biocept, Inc. | Recovery of rare cells using a microchannel apparatus with patterned posts |
US7553932B1 (en) | 2005-04-25 | 2009-06-30 | La Jolla Institute For Allergy And Immunology | Methods of treating viral infection with IL-10 receptor antagonists |
RU2441067C2 (ru) | 2005-09-28 | 2012-01-27 | Цитос Биотехнологи Аг | Конъюгаты интерлейкина-1 и их применение |
US20100068192A1 (en) * | 2005-09-30 | 2010-03-18 | Takara Bio Inc. | Method for Production of T Cell Population |
TWI461436B (zh) | 2005-11-25 | 2014-11-21 | Kyowa Hakko Kirin Co Ltd | 人類cd134(ox40)之人類單株抗體及其製造及使用方法 |
US7704708B2 (en) | 2006-02-13 | 2010-04-27 | Uti Limited Partnership | Monomeric streptavidin muteins |
US7855057B2 (en) | 2006-03-23 | 2010-12-21 | Millipore Corporation | Protein splice variant/isoform discrimination and quantitative measurements thereof |
US7767206B2 (en) | 2006-10-02 | 2010-08-03 | Amgen Inc. | Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto |
EP2476697B1 (en) | 2006-10-17 | 2015-06-17 | Oncotherapy Science, Inc. | Peptide vaccines for cancers expressing MPHOSPH1 polypeptides |
GB0620894D0 (en) | 2006-10-20 | 2006-11-29 | Univ Southampton | Human immune therapies using a CD27 agonist alone or in combination with other immune modulators |
EP2085782B1 (en) | 2006-11-02 | 2017-03-08 | Kyowa Medex CO., LTD. | Method of immunoassaying a component to be measured |
WO2008140573A2 (en) | 2006-11-15 | 2008-11-20 | Invitrogen Dynal As | Methods for reversibly binding a biotin compound to a support |
US20080131415A1 (en) | 2006-11-30 | 2008-06-05 | Riddell Stanley R | Adoptive transfer of cd8 + t cell clones derived from central memory cells |
JP5558828B2 (ja) | 2006-12-28 | 2014-07-23 | ドイチェス クレープスフォルシュングスツェントルム | インビボでの神経膠芽腫細胞の浸潤を阻害するcd95活性の中和 |
CN101226118B (zh) | 2007-01-19 | 2010-06-16 | 中国医学科学院肿瘤研究所 | 一种兼容免疫荧光分析的细胞化学染色方法及其用途 |
KR20080076622A (ko) | 2007-02-16 | 2008-08-20 | 포항공과대학교 산학협력단 | 올리고머화된 단백질 전달체와 이를 이용한 세포내바이러스 벡터 전달 방법 |
JP5754135B2 (ja) | 2007-03-26 | 2015-07-29 | アジェナス インコーポレイテッド | 関心対象のタンパク質の細胞表面ディスプレイ、スクリーニング、および産生 |
EP3357338A1 (en) | 2007-03-30 | 2018-08-08 | Memorial Sloan-Kettering Cancer Center | Constitutive expression of costimulatory ligands on adoptively transferred t lymphocytes |
RU2549701C2 (ru) | 2007-05-07 | 2015-04-27 | Медиммун, Ллк | Анти-icos антитела и их применение в лечении онкологических, связанных с трансплантацией и аутоиммунных заболеваний |
KR101597840B1 (ko) | 2007-08-20 | 2016-02-25 | 넥스테라 에이에스 | pⅦ 파아지 디스플레이 |
NO2227271T3 (pt) | 2007-12-07 | 2018-06-23 | ||
US8479118B2 (en) | 2007-12-10 | 2013-07-02 | Microsoft Corporation | Switching search providers within a browser search box |
KR20180001596A (ko) | 2008-01-18 | 2018-01-04 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 체액 내에서 질병 또는 병태의 시그너쳐의 검출 방법 |
JP2011510653A (ja) | 2008-01-29 | 2011-04-07 | フレッド ハッチンソン キャンサー リサーチ センター | CD161hiおよび/またはIL18Rahiであり、迅速な薬剤流出能力を有するCD8+T細胞の同定 |
AU2009209591B2 (en) | 2008-01-30 | 2012-08-02 | Pieris Ag | Muteins of tear lipocalin having affinity to human c-Met receptor tyrosine kinase and methods for obtaining the same |
WO2009145831A1 (en) | 2008-04-02 | 2009-12-03 | Geisinger Clinic | Treatment of the idiopathic nephrotic syndrome spectrum diseases using basiliximab |
US20120164718A1 (en) | 2008-05-06 | 2012-06-28 | Innovative Micro Technology | Removable/disposable apparatus for MEMS particle sorting device |
JP5173594B2 (ja) | 2008-05-27 | 2013-04-03 | キヤノン株式会社 | 管理装置、画像形成装置及びそれらの処理方法 |
JP5425775B2 (ja) | 2008-06-30 | 2014-02-26 | 協和発酵キリン株式会社 | 抗cd27抗体 |
US8775327B2 (en) | 2008-07-03 | 2014-07-08 | Oracle International Corporation | Combined directory of personal and enterprise application system data |
US20100055098A1 (en) | 2008-08-28 | 2010-03-04 | Facet Biotech Corporation | Method for treating multiple sclerosis patients with anti-il2r antibodies |
CN101446576B (zh) | 2008-12-29 | 2011-06-22 | 江苏省苏微微生物研究有限公司 | 一种微囊藻毒素-lr单抗免疫亲和柱的制备和使用方法 |
WO2010080032A2 (en) | 2009-01-09 | 2010-07-15 | Stichting Het Nederlands Kanker Instituut | Bead-assisted viral transduction |
CN102724993B (zh) | 2009-04-17 | 2016-04-27 | 纽约大学 | 靶向tnf家族受体并拮抗tnf作用的肽、组合物、方法及其用途 |
WO2010126890A1 (en) | 2009-04-27 | 2010-11-04 | Facet Biotech Corporation | Methods for monitoring the efficacy of anti-il-2r antibodies in multiple sclerosis patients |
US20110053209A1 (en) | 2009-08-31 | 2011-03-03 | Facet Biotech Corporation | Use of an immunoregulatory nk cell population for monitoring the efficacy of anti-il-2r antibodies in multiple sclerosis patients |
WO2011053971A2 (en) | 2009-11-02 | 2011-05-05 | Fina Biosolutions, Llc | Method for enhancing the sensitivity of antibody based assays |
US20120321665A1 (en) | 2009-12-14 | 2012-12-20 | Benaroya Research Institute At Virginia Mason | Compositions and methods for treating airway inflammatory diseases |
EP2363501A1 (en) | 2010-03-02 | 2011-09-07 | Universitätsklinikum Hamburg-Eppendorf | Method for isolating target cells |
WO2011130434A2 (en) | 2010-04-13 | 2011-10-20 | Celldex Therapeutics Inc. | Antibodies that bind human cd27 and uses thereof |
EP2601521B1 (en) | 2010-08-06 | 2018-05-02 | Ludwig-Maximilians-Universität München | Identification of t cell target antigens |
WO2012058627A2 (en) | 2010-10-29 | 2012-05-03 | Miqin Zhang | Pre-targeted nanoparticle system and method for labeling biological particles |
BR122021026169B1 (pt) | 2010-12-09 | 2023-12-12 | The Trustees Of The University Of Pennsylvania | Uso de uma célula |
CA2824278C (en) | 2010-12-20 | 2022-09-20 | The Rockefeller University | Modulating agonistic tnfr antibodies |
AU2012230780B2 (en) | 2011-03-23 | 2016-10-27 | Fred Hutchinson Cancer Center | Method and compositions for cellular immunotherapy |
US8398282B2 (en) | 2011-05-12 | 2013-03-19 | Delphi Technologies, Inc. | Vehicle front lighting assembly and systems having a variable tint electrowetting element |
TR201811128T4 (tr) | 2011-07-18 | 2018-08-27 | Iba Gmbh | Bir hedef hücrenin tersinir şekilde boyama yöntemi. |
GB201116092D0 (en) | 2011-09-16 | 2011-11-02 | Bioceros B V | Antibodies and uses thereof |
KR102134932B1 (ko) | 2011-11-11 | 2020-07-17 | 프레드 헛친슨 켄서 리서치 센터 | 암을 위한 사이클린 a1―표적화된 t―세포 면역요법 |
EP2814846B1 (en) | 2012-02-13 | 2020-01-08 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
WO2013126726A1 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Double transgenic t cells comprising a car and a tcr and their methods of use |
EP2817625A2 (en) | 2012-02-23 | 2014-12-31 | Stage Cell Therapeutics GmbH | Chromatographic isolation of cells and other complex biological materials |
MY175224A (en) | 2012-03-15 | 2020-06-16 | Janssen Biotech Inc | Human anti-cd27 antibodies, methods, and uses |
CN104395462B (zh) | 2012-05-03 | 2017-09-26 | 弗雷德哈钦森癌症研究中心 | 增强亲和力的t细胞受体及其制备方法 |
UA114108C2 (uk) | 2012-07-10 | 2017-04-25 | Борд Оф Ріджентс, Дзе Юніверсіті Оф Техас Сістем | Моноклональне антитіло для застосування в діагностиці і терапії злоякісних пухлин і аутоімунного захворювання |
RS61345B1 (sr) | 2012-08-20 | 2021-02-26 | Hutchinson Fred Cancer Res | Postupak i kompozicije za ćelijsku imunoterapiju |
WO2014039044A1 (en) | 2012-09-06 | 2014-03-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of producing t memory stem cell populations |
EP2711418B1 (en) | 2012-09-25 | 2017-08-23 | Miltenyi Biotec GmbH | Method for polyclonal stimulation of T cells by flexible nanomatrices |
ES2743738T3 (es) | 2012-10-02 | 2020-02-20 | Memorial Sloan Kettering Cancer Center | Composiciones y métodos para inmunoterapia |
WO2014076277A1 (en) * | 2012-11-16 | 2014-05-22 | Iba Gmbh | Streptavidin muteins and methods of using them |
JP5372297B1 (ja) | 2012-12-20 | 2013-12-18 | 三菱電機株式会社 | 車載装置及びプログラム |
EP3027210A1 (en) | 2013-08-02 | 2016-06-08 | Aduro Biotech Holdings, Europe B.V. | Combining cd27 agonists and immune checkpoint inhibition for immune stimulation |
US9108442B2 (en) | 2013-08-20 | 2015-08-18 | Ricoh Company, Ltd. | Image forming apparatus |
CA2933707A1 (en) | 2013-12-20 | 2015-06-25 | Fred Hutchinson Cancer Research Center | Tagged chimeric effector molecules and receptors thereof |
BR112016022345A2 (pt) | 2014-03-31 | 2017-10-10 | Genentech Inc | terapia de combinação compreendendo agentes antiangiogênese e agonistas de ligação de ox40 |
CA2943262A1 (en) | 2014-03-31 | 2015-10-08 | Genentech, Inc. | Anti-ox40 antibodies and methods of use |
MY184699A (en) | 2014-04-16 | 2021-04-18 | Juno Therapeutics Gmbh | Methods, kits and apparatus for expanding a population of cells |
MA51794A (fr) | 2014-04-23 | 2020-05-06 | Juno Therapeutics Inc | Procédés d'isolation, de culture et de modification génétique de populations de cellules immunitaires pour thérapie adoptive |
EP3134512B1 (en) | 2014-04-24 | 2019-01-02 | Miltenyi Biotec GmbH | Method for automated generation of genetically modified t cells |
CN106662584B (zh) | 2014-04-30 | 2020-05-05 | Iba股份有限公司 | 分离靶细胞的方法 |
EP2955196A1 (en) | 2014-06-10 | 2015-12-16 | Effimune | Antibodies directed against CD127 |
EP3161003A2 (en) | 2014-06-27 | 2017-05-03 | Apogenix GmbH | Combination of cd95/cd95l inhibition and cancer immunotherapy |
BR112017007393A2 (pt) | 2014-10-18 | 2017-12-19 | Pfizer | composições de anticorpo anti-il-7r |
WO2016166568A1 (en) | 2015-04-16 | 2016-10-20 | Juno Therapeutics Gmbh | Methods, kits and apparatus for expanding a population of cells |
MA45489A (fr) | 2015-10-22 | 2018-08-29 | Juno Therapeutics Gmbh | Procédés de culture de cellules, kits et appareil associés |
JP7195141B2 (ja) | 2015-10-22 | 2022-12-23 | ジュノ セラピューティクス ゲーエムベーハー | 形質導入のための方法、キット、作用物質および装置 |
AU2016363025B2 (en) | 2015-12-03 | 2021-04-08 | Juno Therapeutics, Inc. | Modified chimeric receptors and related compositions and methods |
CN110418802A (zh) | 2017-01-20 | 2019-11-05 | 朱诺治疗学有限公司 | 细胞表面缀合物及相关的细胞组合物和方法 |
NZ758485A (en) | 2017-04-27 | 2024-02-23 | Juno Therapeutics Gmbh | Oligomeric particle reagents and methods of use thereof |
KR20210057730A (ko) | 2018-08-09 | 2021-05-21 | 주노 쎄러퓨티크스 인코퍼레이티드 | 조작 세포 및 이의 조성물 생성 방법 |
SG11202104355SA (en) | 2018-10-31 | 2021-05-28 | Juno Therapeutics Gmbh | Methods for selection and stimulation of cells and apparatus for same |
-
0
- MA MA045488A patent/MA45488A/fr unknown
-
2016
- 2016-10-20 IL IL307934A patent/IL307934A/en unknown
- 2016-10-20 EP EP16801293.8A patent/EP3365434A1/en active Pending
- 2016-10-20 CA CA3002745A patent/CA3002745A1/en active Pending
- 2016-10-20 MX MX2018004874A patent/MX2018004874A/es unknown
- 2016-10-20 NZ NZ741878A patent/NZ741878A/en unknown
- 2016-10-20 JP JP2018521024A patent/JP6895959B2/ja active Active
- 2016-10-20 CN CN202310604691.5A patent/CN117106716A/zh active Pending
- 2016-10-20 CN CN201680075211.9A patent/CN108431210B/zh active Active
- 2016-10-20 IL IL258844A patent/IL258844B2/en unknown
- 2016-10-20 WO PCT/IB2016/001618 patent/WO2017068421A1/en active Application Filing
- 2016-10-20 KR KR1020187014396A patent/KR20180100110A/ko active Search and Examination
- 2016-10-20 BR BR112018008081A patent/BR112018008081A2/pt active Search and Examination
- 2016-10-20 RU RU2018118575A patent/RU2761557C2/ru active
- 2016-10-20 AU AU2016341529A patent/AU2016341529B2/en active Active
- 2016-10-20 US US15/770,179 patent/US11466253B2/en active Active
- 2016-10-20 SG SG11201803330WA patent/SG11201803330WA/en unknown
-
2018
- 2018-04-19 MX MX2022012147A patent/MX2022012147A/es unknown
- 2018-04-19 MX MX2022012148A patent/MX2022012148A/es unknown
- 2018-04-20 PH PH12018500860A patent/PH12018500860A1/en unknown
-
2019
- 2019-01-28 HK HK19101410.9A patent/HK1258931A1/zh unknown
-
2021
- 2021-06-08 JP JP2021095512A patent/JP7390334B2/ja active Active
-
2022
- 2022-10-07 US US18/045,137 patent/US20230295567A1/en active Pending
-
2023
- 2023-08-09 JP JP2023129681A patent/JP2023138707A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
MA45488A (fr) | 2018-08-29 |
JP6895959B2 (ja) | 2021-06-30 |
CN117106716A (zh) | 2023-11-24 |
JP2023138707A (ja) | 2023-10-02 |
AU2016341529A1 (en) | 2018-05-10 |
RU2018118575A (ru) | 2019-11-27 |
NZ741878A (en) | 2024-03-22 |
IL307934A (en) | 2023-12-01 |
WO2017068421A1 (en) | 2017-04-27 |
RU2018118575A3 (pt) | 2020-07-28 |
HK1258931A1 (zh) | 2019-11-22 |
EP3365434A1 (en) | 2018-08-29 |
KR20180100110A (ko) | 2018-09-07 |
MX2022012147A (es) | 2023-03-01 |
JP7390334B2 (ja) | 2023-12-01 |
CN108431210B (zh) | 2023-05-23 |
PH12018500860A1 (en) | 2018-11-05 |
IL258844B2 (en) | 2024-03-01 |
RU2761557C2 (ru) | 2021-12-09 |
CN108431210A (zh) | 2018-08-21 |
AU2016341529B2 (en) | 2023-03-30 |
US20190136186A1 (en) | 2019-05-09 |
MX2022012148A (es) | 2023-03-01 |
JP2021137025A (ja) | 2021-09-16 |
CA3002745A1 (en) | 2017-04-27 |
IL258844B1 (en) | 2023-11-01 |
US11466253B2 (en) | 2022-10-11 |
JP2018531035A (ja) | 2018-10-25 |
SG11201803330WA (en) | 2018-05-30 |
US20230295567A1 (en) | 2023-09-21 |
IL258844A (en) | 2018-06-28 |
MX2018004874A (es) | 2018-12-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018008081A2 (pt) | métodos para a cultura de células e kits e aparelho para os mesmos | |
BR112018008061A2 (pt) | métodos para a cultura de células e kits e aparelhos para os mesmos | |
BR112018008111A2 (pt) | métodos, kits, agentes e aparelhos para transdução | |
BR112019000512A2 (pt) | anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos de tratamento de uma doença, para produzir um anticorpo biespecífico e para detectar se a reticulação entre as células que expressam cd40 e cd137 ocorre em uma amostra, uso de um anticorpo multiespecífico, e, kit | |
CY1124717T1 (el) | Μεθοδοι, kit και συσκευη για επεκταση πληθυσμου κυτταρων | |
BR112015001620A2 (pt) | composição de meio de cultura, e método para cultivo de célula ou tecido usando-se dita composição | |
BR112015027996A8 (pt) | Organoides compreendendo células renais isoladas e suas utilizações | |
EP4339288A3 (en) | Oligonucleotide probes and uses thereof | |
GB2525104A (en) | Massively parallel single cell analysis | |
BR112017018941B8 (pt) | Molécula de ligação a cd20, seu uso, composição e método in vitro para direcionar a morte mediada por complemento de uma célula que expressa cd20 | |
BR112016019940A2 (pt) | edição de genoma sem nucleases | |
BR112017014551A2 (pt) | ?anticorpo, construção de ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos para tratamento de uma doença, para produção de um anticorpo biespecífico e para detecção da possível ocorrência de reticulação entre células com expressão de cd3 e cd20 em uma amostra derivada de um paciente, uso de um anticorpo biespecífico, e, kit? | |
BRPI0921687A8 (pt) | Composto , conjugado , uso de um composto , composição farmacêutica, processo para preparar uma composição famacêutica , método para tratar um mamífero em necessidade do mesmo ,e, método para tratar ou prevenir um tumor em um mamífero. | |
BR112015022322A2 (pt) | sistemas e métodos para detecção de células com o uso de partículas de transdução projetadas | |
BR112017006469A2 (pt) | composições e métodos para inibição de expressão do gene hao1 (hidroxiácido oxidase 1 (glicolato oxidase)) | |
BR112015017174A2 (pt) | preparação de enxertos de nervo de tecido manipulado com matriz extracelular modificada para reparo de lesão de nervo periférico | |
BR112015016005A2 (pt) | preparação de amostra em um suporte sólido | |
BRPI0814343A2 (pt) | Materiais e métodos para a seleção da sexagem do esperma | |
BR112013022832A2 (pt) | linhagens de células de baixo teor de fucose e usos das mesmas | |
CO6190565A2 (es) | Aptameros, metodos para su seleccion y usos | |
BR112014003139A2 (pt) | musgo de turfa umectável resistente à lixiviação, método de preparação, e método de uso | |
BR112017015203A2 (pt) | anticorpos de penetração celular | |
BR112015019865A2 (pt) | composições de copolímero de alfa-olefina de alta viscosidade e métodos de preparação e uso das mesmas | |
BR112018072195A2 (pt) | amplificação de incompatibilidade otimizada multiplexado (moma) - pcr de tempo real para avaliar o câncer | |
BR112022016490A2 (pt) | Métodos para enriquecimento ex vivo e expansão de células t reativas tumorais e composições relacionadas das mesmas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25G | Requested change of headquarter approved |
Owner name: JUNO THERAPEUTICS GMBH (DE) |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] |